David Urech

Chairman Numab Innovation
Biochemistry
Numab
Switzerland

Doctor Biochemistry
Biography

David is a co-founder of Numab. From 2004 until 2010, David was at Esbatech, as Head of Research & Development. He designed Esbatech’s antibody discovery platform, and was responsible for the discovery and preclinical development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment age-related macular edema. His work on the pharmacokinetic properties of antibody fragments led to the development of ESBA105, a TNF-inhibitory scFv – the first antibody fragment to be applied topically by eye drops. David is an inventor on numerous patents and patent applications and has published widely in leading peer-reviewed journals. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.

Research Intrest

 Biochemistry

Global Scientific Words in Biochemistry